MC
VRTX icon

Moors & Cabot’s Vertex Pharmaceuticals VRTX Stock Holding History

Moors & Cabot’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$5K – 923
2022
Q1 		$5K Buy
100
+98
+4,900% +$23.3K ﹤0.01% 866
2021
Q4 		$2K Buy
+2
New +$389 ﹤0.01% 898

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Moors & Cabot's VRTX Position: Q1 2026 in Review

Moors & Cabot increased its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, buying an estimated $35.9K and bringing the position to 3,556 shares worth $1.59M. The position accounts for 0.07% of the portfolio, ranked #258.

Moors & Cabot first reported a position in VRTX in Q4 2019 and has held it in 23 quarters since. The position peaked at $2.67M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Moors & Cabot held 3,556 shares of Vertex Pharmaceuticals worth $1.59M as of Q1 2026.
  • Moors & Cabot bought 77 Vertex Pharmaceuticals shares in Q1 2026, an estimated $35.9K.
  • Vertex Pharmaceuticals made up 0.07% of Moors & Cabot's portfolio in Q1 2026, its #258 holding.
  • Moors & Cabot first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • Moors & Cabot's Vertex Pharmaceuticals position peaked at $2.67M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.